Aura Biosciences Inc
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
AURA$7.65-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Additional · Accumulated · Total | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Paid-In · Accumulated · Other Comprehensive · Stockholders’ | ||||||
| Shares | Amount | Capital | Deficit | Loss Amount | Equity | |
| Balance, December 31, 2022 | 37,771,918 | $— | $406,555 | $(210,900) | $(72) | 195,583 |
| Issuance of common stock - follow-on offering, net of issuance costs of $444 | 11,000,000 | — | 92,616 | — | — | 92,616 |
| Issuance of common stock under ATM facility, net of issuance costs | 261,807 | — | 3,170 | — | — | 3,170 |
| Stock-based compensation expense | — | — | 8,772 | — | — | 8,772 |
| Employee Stock Purchase Plan Issuance | 14,911 | — | 128 | — | — | 128 |
| Vesting of restricted stock | 43,162 | — | 0 | — | — | — |
| Stock option exercises | 258,990 | — | 1,376 | — | — | 1,376 |
| Unrealized gain on marketable securities | — | — | 0 | — | 611 | 611 |
| Net loss | — | — | — | (76,408) | — | (76,408) |
| Balance, December 31, 2023 | 49,350,788 | — | 512,617 | (287,308) | 539 | 225,848 |
| Additional · Accumulated · Total | ||||||
| Common Stock · Paid-In · Accumulated · Other Comprehensive · Stockholders’ | ||||||
| Shares | Amount | Capital | Deficit | Loss Amount | Equity | |
| Balance, December 31, 2021 | 29,211,643 | $— | $304,452 | $(152,137) | $— | 152,315 |
| Issuance of common stock - follow-on offering, net of issuance costs of $263 | 7,705,000 | — | 86,650 | — | — | 86,650 |
| Issuance of common stock under ATM facility, net of issuance costs of $336 | 732,189 | — | 8,549 | — | — | 8,549 |
| Stock-based compensation expense | — | — | 6,412 | — | 6,412 | |
| Vesting of restricted stock | 51,444 | — | — | — | — | |
| Stock option exercises | 71,642 | — | 430 | — | — | 430 |
| Unrealized loss on marketable securities | — | — | — | — | (72) | (72) |
| Other | — | — | 62 | — | — | 62 |
| Net loss | — | — | — | (58,763) | — | (58,763) |
| Balance, December 31, 2022 | 37,771,918 | — | $406,555 | $(210,900) | $(72) | $195,583 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.